$1.7 M

TENX Mkt cap, 14-Dec-2018
Tenax Therapeutics Net income (Q3, 2018)1.5 M
Tenax Therapeutics Cash, 30-Sep-20183.3 M

Tenax Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

158.9k49.3k

Revenue growth, %

(69%)(100%)

Cost of goods sold

129.8k

Gross profit

29.1k

Gross profit Margin, %

18%

R&D expense

3.0m6.7m13.1m3.5m

General and administrative expense

7.2m6.2m5.7m

Operating expense total

16.8m14.9m52.7m9.2m

EBIT

(16.6m)(14.8m)(52.7m)

EBIT margin, %

(10452%)(30063%)

Interest expense

2.2m49.1k

Income tax expense

(8.0m)

Net Income

19.5m14.1m43.9m8.8m

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

55.7k41.9k

Cost of goods sold

3.4k410.0

Gross profit

52.4k41.5k

Gross profit Margin, %

94%99%

R&D expense

748.6k689.7k966.5k1.7m2.5m3.9m3.4m3.2m2.1m1.2m254.0k58.6k311.2k362.6k

General and administrative expense

1.4m1.2m1.8m1.2m1.3m1.4m1.8m1.1m1.2m1.6m1.2m

Operating expense total

2.2m2.5m2.4m3.1m3.7m5.7m4.7m4.5m3.5m3.0m1.3m1.2m1.9m1.6m

Interest expense

1.4m70.0k46.3k1.1k404.0

Net Income

3.5m3.4m2.2m3.0m3.5m5.4m4.6m4.3m3.3m3.0m1.2m1.2m1.9m1.5m

Tenax Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

58.3m7.9m10.0m1.6m

Accounts Receivable

36.4k76.5k72.6k50.2k

Current Assets

59.0m17.5m13.6m8.1m

PP&E

124.4k50.3k19.1k9.9k

Goodwill

11.3m11.3m

Total Assets

93.4m82.9m23.3m9.9m

Accounts Payable

411.1k1.2m727.6k611.9k

Short-term debt

Current Liabilities

2.6m4.5m6.2m1.0m

Long-term debt

346.9k100.2k

Total Debt

346.9k100.2k

Total Liabilities

10.5m12.5m6.2m1.0m

Additional Paid-in Capital

219.5m221.1m221.8m222.4m

Retained Earnings

(136.6m)(150.7m)(204.7m)(213.5m)

Total Equity

82.9m70.4m17.1m8.9m

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

1.1 x1.2 x1.4 x1.1 x

Tenax Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(19.5m)(14.1m)(43.9m)(8.8m)

Depreciation and Amortization

150.5k148.1k19.0k13.6k

Inventories

99.2k

Accounts Payable

(2.1m)2.7m1.9m(5.0m)

Cash From Operating Activities

(9.3m)(9.7m)(15.9m)(12.1m)

Purchases of PP&E

(9.8k)(4.2k)(2.9k)(4.5k)

Cash From Investing Activities

(147.0k)(40.9m)22.2m3.7m

Cash From Financing Activities

66.9m280.6k(100.2k)

Interest Paid

30.3k3.5k1.5k

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(5.8m)(9.1m)(2.2m)(3.0m)(6.6m)(5.4m)(10.0m)(14.3m)(3.3m)6.3m(7.5m)(1.2m)(3.1m)(4.6m)

Depreciation and Amortization

74.9k111.2k38.5k12.7k25.0k4.6k9.7k14.5k4.0k7.5k10.6k2.6k5.4k7.6k

Inventories

1.2k1.8k

Accounts Payable

(684.5k)(1.1m)78.6k1.9m830.0k669.5k(987.1k)(3.9m)(5.2m)(684.8k)(331.9k)(339.5k)

Cash From Operating Activities

(3.6m)(6.3m)(2.0m)(3.8m)(6.5m)(3.3m)(8.5m)(12.8m)(4.0m)(9.6m)(10.9m)(1.6m)(2.7m)(4.3m)

Purchases of PP&E

(9.8k)(35.6m)(16.7k)(16.7k)(2.9k)(2.9k)(2.9k)(3.3k)(3.3k)(4.5k)(3.1k)(5.8k)(5.8k)

Cash From Investing Activities

(68.9k)(113.0k)(34.6m)(380.9k)3.8m2.9m6.8m9.8m1.1m1.9m2.6m2.9m5.0m6.0m

Cash From Financing Activities

5.4m12.0m196.4k(51.8k)(100.2k)

Interest Paid

27.6k28.9k655.01.1k1.5k

Tenax Therapeutics Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Tenax Therapeutics Operating Metrics

FY, 2016

Patents Issued

7

Phase III Trials Products

1

Preclinical Phase Products

1
Report incorrect company information